What You Should Know:

你应该知道的：

–

–

Ezra

以斯拉

, a innovator in

，一个创新者在

AI-driven

人工智能驱动的

cancer screening, today announced that its advanced Ezra Flash AI model has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

癌症筛查，今天宣布其先进的Ezra Flash AI模型已获得美国食品药品监督管理局（FDA）的510(k)许可。

– The FDA clearance expands the capabilities of its AI-powered platform to provide faster, more affordable, and higher-quality full-body MRI scans.

– FDA的批准扩展了其人工智能平台的能力，可以提供更快、更实惠、更高质量的全身MRI扫描。

Ezra Flash AI for MRI Image Quality

Ezra Flash AI 用于 MRI 图像质量

Ezra Flash, a Class II medical device, now enhances image quality for neuro, abdomen, and pelvis MRI scans, making it applicable across the entire body. This advancement allows Ezra to accelerate scan times and improve diagnostic accuracy, bringing the company closer to its goal of offering a 15-minute, $500 full-body MRI scan in 2026..

Ezra Flash是一款II类医疗器械，现在可提升神经、腹部和骨盆MRI扫描的图像质量，从而实现全身适用。这一进步使Ezra能够加快扫描时间并提高诊断准确性，让公司更接近于2026年实现15分钟、500美元全身MRI扫描的目标。

Ezra’s technology is currently available at 74 locations across 29 cities in the U.S.

Ezra的技术目前在美国29个城市的74个地点可用。

“This FDA clearance marks another milestone in our journey towards

“这一FDA许可标志着我们征程中的又一个重要里程碑

making affordable and fast full-body MRIs a reality,” said Emi Gal, founder and CEO of Ezra. “Our goal is to launch a 15-minute, $500 full body MRI scan in 2026, and this new FDA clearance is an important step in that direction.”

Ezra创始人兼首席执行官Emi Gal表示：“让价格实惠且快速的全身核磁共振成像成为现实。我们的目标是在2026年推出15分钟、500美元的全身核磁共振扫描，而这一新的FDA批准是朝这个方向迈出的重要一步。”